Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
LEO Pharma
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed and dated informed consent has been obtained
Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs and/or trunk. The lesions must have a total size suitable for application of 6 different products.
Age 18 years or above
Outpatients
Female subjects must be of either
* non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus or has tubal ligation) or,
* child-bearing potential provided there is a confirmed negative pregnancy test prior to trial treatment to rule out pregnancy.
You may not be if
Female subjects who are breast feeding
Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:
* Etanercept - within 4 weeks prior to randomisation and during the trial
* Adalimumab, infliximab - within 8 weeks prior to randomisation and during the trial
* Ustekinumab - within 16 weeks prior to randomisation and during the trial
* Other products - within 4 weeks/5 half-lives prior to randomisation and during the trial (whichever is longer)
Systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within the 4-week period prior to randomisation and during the trial,
Subjects using phototherapy within the following time periods prior to randomisation and during the trial:
* PUVA: 4 weeks
* UVB: 2 weeks
Subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the trial:
* Potent or very potent (WHO group III-IV) corticosteroids
Subjects using one of the following topical drugs for the treatment of psoriasis within 2 weeks prior to randomisation and during the trial:
* WHO group I-II corticosteroids (except if used for treatment of scalp and/or facial psoriasis)
* Topical retinoids, Vitamin D analogues, Topical immunomodulators (e.g. calcineurin inhibitors), Tar products, Salicylic acid
Subjects using emollients on the selected plaques within 1 week before randomisation and during the trial
Initiation of, or expected changes to concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, antimalarial drugs, lithium and ACE inhibitors) within 2 weeks prior to the randomisation and during the trial
Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis
Clareo Health | A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
